Denali Therapeutics (DNLI) Retained Earnings (2017 - 2025)
Denali Therapeutics (DNLI) has disclosed Retained Earnings for 9 consecutive years, with -$1.9 billion as the latest value for Q3 2025.
- On a quarterly basis, Retained Earnings fell 35.02% to -$1.9 billion in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.9 billion, a 35.02% decrease, with the full-year FY2024 number at -$1.5 billion, down 239444.32% from a year prior.
- Retained Earnings was -$1.9 billion for Q3 2025 at Denali Therapeutics, down from $939000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $2.0 million in Q1 2025 to a low of -$1.9 billion in Q3 2025.
- A 5-year average of -$423.0 million and a median of -$9.3 million in 2022 define the central range for Retained Earnings.
- Peak YoY movement for Retained Earnings: tumbled 263163.67% in 2021, then skyrocketed 257.18% in 2025.
- Denali Therapeutics' Retained Earnings stood at -$645.0 million in 2021, then skyrocketed by 98.93% to -$6.9 million in 2022, then skyrocketed by 109.34% to $643000.0 in 2023, then plummeted by 239444.32% to -$1.5 billion in 2024, then dropped by 24.95% to -$1.9 billion in 2025.
- Per Business Quant, the three most recent readings for DNLI's Retained Earnings are -$1.9 billion (Q3 2025), $939000.0 (Q2 2025), and $2.0 million (Q1 2025).